Canada - English - Health Canada

abbvie corporation - fluorometholone - suspension - 0.1% - fluorometholone 0.1% - corticosteroids

Canada - English - Health Canada

allergan inc - fluorometholone - suspension - 0.25% - fluorometholone 0.25% - corticosteroids

Canada - English - Health Canada

novartis pharmaceuticals canada inc - fluorometholone acetate - suspension - 0.1% - fluorometholone acetate 0.1% - corticosteroids

United States - English - NLM (National Library of Medicine)

allergan, inc. - fluorometholone (unii: sv0csg527l) (fluorometholone - unii:sv0csg527l) - fml ® ointment is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. fml ® ointment is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. fml ® ointment is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

United States - English - NLM (National Library of Medicine)

allergan, inc. - fluorometholone (unii: sv0csg527l) (fluorometholone - unii:sv0csg527l) - fml forte ® suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. fml forte ® suspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. fml forte ® suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

United States - English - NLM (National Library of Medicine)

allergan, inc. - fluorometholone (unii: sv0csg527l) (fluorometholone - unii:sv0csg527l) - fml ® suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. fml ® suspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye, and fungal diseases of ocular structures. fml ® suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

Malta - English - Medicines Authority

s.a alcon-couvreur n.v. - fluorometholone acetate 1 mg/ml - eye drops, suspension

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

abbvie ltd - fluorometholone - eye drops - 1mg/1ml

Kenya - English - Pharmacy and Poisons Board

helix pharma (pvt) limited hakimsons house a-56 s.i.t.e. manghopir road - fluorometholone - eye drops - 1.0mg fluorometholone usp per 1ml - ophthalmologicals: corticosteroids

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - fluorometholone -